US · DXR
Daxor Corporation
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Oak Ridge, TN 37830
- Website
- daxor.com
Price · as of 2024-12-31
$10.44
Market cap 59.76M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $327.01 | +3,032.28% |
| Intrinsic Value(DCF) | $14.29 | +36.88% |
| Graham-Dodd Method(GD) | $7.95 | -23.9% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $9.61 | $22.00 | $10.93 | $1.98 | $2.35 |
| 2011 | $8.83 | $93.63 | $1.80 | $0.00 | $17.43 |
| 2012 | $7.27 | $576.56 | $0.00 | $6.97 | $0.00 |
| 2013 | $7.40 | $1,143.12 | $0.00 | $0.00 | |
| 2014 | $5.56 | $383.82 | $0.00 | $4.76 | |
| 2015 | $7.97 | $21,662.81 | $0.00 | $0.00 | |
| 2016 | $7.25 | $363.49 | $7.25 | $5.51 | |
| 2017 | $6.01 | $637.97 | $0.00 | $1.57 | $46.56 |
| 2018 | $15.65 | $31.42 | $0.00 | $2.31 | |
| 2019 | $12.17 | $1,090.64 | $0.00 | $2.46 | |
| 2020 | $12.15 | $741.08 | $0.00 | $1.82 | |
| 2021 | $11.08 | $146.21 | $0.00 | $11.12 | |
| 2022 | $9.72 | $145.82 | $0.00 | $6.39 | |
| 2023 | $7.90 | $1,401.39 | $292.32 | $7.65 | |
| 2024 | $8.00 | $327.01 | $18.69 | $7.95 | $0.00 |
AI valuation
Our deep-learning model estimates Daxor Corporation's (DXR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $327.01
- Current price
- $10.44
- AI upside
- +3,032.28%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$14.29
+36.88% upside
Graham-Dodd
$7.95
-23.9% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DXR | Daxor Corporation | $10.44 | 59.76M | +3,032% | +37% | -24% | — | 72.23 | 1.08 | 18.18 | 19.18 | 88.61 | 1.08 | 100.00% | 29.16% | 25.17% | 1.54% | 1.74% | 1.50% | 0.02 | 7.30 | 0.17 | 0.09 | 0.35 | 8152.00% | -9384.00% | -10070.00% | 0.07% | 0.23 | 0.07% | 0.00% | 0.00% | 0.07% | 63.52 | 1536.03 | 18.52 | 28.75 |
| ACET | Adicet Bio, Inc. | $7.25 | 69.44M | — | — | — | — | -0.60 | 0.37 | — | 0.81 | — | 0.37 | 0.00% | — | — | -65.65% | -433.12% | -54.79% | 0.09 | -31903.75 | 9.29 | 9.09 | 0.35 | -5982.00% | — | -477.00% | -133.68% | -4.76 | -317.32% | 0.00% | 0.00% | 0.00% | 0.70 | 0.95 | — | -2.95 |
| ADAG | Adagene Inc. | $2.96 | 111.61M | +945% | -54% | — | +2,625% | -2.19 | 1.45 | 708.59 | -0.20 | -2.88 | 1.45 | -797.49% | -34835.42% | -32386.45% | -55.21% | 216.17% | -32.61% | 0.37 | -42.20 | 2.30 | 2.23 | 2.11 | 7593.00% | -9943.00% | 419.00% | -40.66% | -0.78 | 178.88% | 0.00% | 0.00% | 0.00% | -0.18 | -0.22 | 62.29 | -4.41 |
| BEAT | HeartBeam, Inc. | $1.51 | 52.01M | — | — | — | — | -3.00 | 35.28 | — | -2.82 | -216.03 | 35.28 | 0.00% | — | — | -221.11% | 4079.38% | -190.60% | 0.00 | — | 1.71 | 1.47 | 0.12 | 139.00% | — | 1881.00% | -25.14% | -8.92 | 3009.64% | 0.00% | 0.00% | 0.00% | -2.81 | -3.82 | — | -22.07 |
| CRVO | CervoMed Inc. | $3.99 | 36.92M | — | — | — | — | -1.10 | 0.46 | — | 1.16 | -0.75 | 0.46 | 0.00% | — | — | -69.95% | 26851.40% | -61.41% | 0.00 | — | 11.11 | 10.61 | 0.49 | 14634.00% | — | 12189.00% | -92.65% | -4.26 | 24352.48% | 0.00% | 0.00% | 6.76% | 1.16 | 1.28 | — | 0.16 |
| GANX | Gain Therapeutics, Inc. | $2.61 | 100.39M | +1,143% | — | — | — | -2.11 | 5.86 | — | -1.64 | — | 5.97 | 0.00% | — | — | -204.95% | 729.11% | -132.83% | 0.09 | — | 2.97 | 2.85 | 0.48 | -4795.00% | -10000.00% | 8.00% | -43.93% | -4.83 | 677.01% | 0.00% | 0.00% | 0.00% | -1.64 | -1.76 | — | -8.76 |
| GEG | Great Elm Group, Inc. | $2.05 | 56.61M | +3,968% | +14% | +137% | — | 4.89 | 1.08 | 4.66 | 1.39 | — | 1.31 | -0.66% | -49.05% | 79.01% | 23.38% | -51.59% | 10.56% | 0.89 | -1.93 | 14.34 | 11.85 | 1.33 | -81274.00% | -851.00% | -4210.00% | -11.85% | -0.94 | -58.38% | 0.00% | 0.00% | 9.52% | -3.64 | -3.24 | 1.79 | -27.91 |
| LITS | Lite Strategy, Inc. | $1.13 | 41.55M | +12,712% | — | — | — | -1.77 | 1.66 | — | -0.60 | — | 1.66 | 0.00% | — | — | -63.84% | 545.04% | -53.45% | 0.00 | — | 13.50 | 13.30 | 1.05 | -18951.00% | -10000.00% | -5871.00% | -73.96% | -15.39 | 650.87% | 0.00% | 0.00% | 50.76% | -0.58 | -0.49 | — | -20.49 |
| NEPH | Nephros, Inc. | $3.91 | 41.55M | +6,452% | +183% | -80% | -99% | 234.68 | 2.02 | 1.23 | 66.16 | — | 2.39 | 61.59% | 0.04% | 0.52% | 0.87% | 0.08% | 0.64% | 0.16 | 6.00 | 5.31 | 3.55 | -10.35 | -10467.00% | -53.00% | -17274.00% | -3.15% | -0.31 | -9.02% | 0.00% | 0.00% | 0.00% | 2502.93 | -27.45 | 1.06 | -12.07 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| XBIT | XBiotech Inc. | $2.26 | 68.9M | — | — | — | — | -2.57 | 0.54 | — | 1.76 | -4.62 | 0.54 | 0.00% | — | — | -19.21% | -219.51% | -18.10% | 0.06 | -52.63 | 11.56 | 11.49 | 4.51 | 5556.00% | — | 6905.00% | -32.59% | -2.05 | -166.91% | 0.00% | 0.00% | 0.00% | 1.49 | 1.97 | — | 3.15 |
About Daxor Corporation
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
- CEO
- Michael Richard Feldschuh
- Employees
- 37
- Beta
- 0.03
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($14.29 ÷ $10.44) − 1 = +36.88% (DCF, example).